Provisional Recommendation for the Use of Zoster Vaccine. By the Advisory Committee on Immunization Practices, Centers for Disease Control. (The Centers, Atlanta, Georgia) 2006. 53 p.
Full Text at: www.cdc.gov/nip/ACIP/slides/oct06/01_Herpes_Zoster/zoster-4-harpaz.pdf
[“The Advisory Committee on Immunization Practices (ACIP), has recommended people age 60 and older receive a new vaccine to prevent herpes zoster, or shingles, a condition that often leads to debilitating chronic pain. The ACIP voted to recommend a newly licensed zoster vaccine, Zostavax, to protect against shingles be given to all people age 60 and older, including those who have had a previous episode of shingles. Zostavax reduced the occurrence of shingles by about 50 percent and post herpetic neuralgia (pain persisting after an episode of shingles) by 67 percent. While the ability for the vaccine to prevent shingles declined with age, the risk of chronic pain among those older vaccinated persons who still developed shingles was lowered.” Press Release (October 26, 2006) 1.]